{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981469442883840.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.21189"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.21189"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-200606000-00026"}},{"identifier":{"@type":"NAID","@value":"30015138448"}}],"dc:title":[{"@value":"Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380583650435866114","@type":"Researcher","foaf:name":[{"@value":"Yoon‐Seon Lee"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469442883973","@type":"Researcher","foaf:name":[{"@value":"Dong Jin Suh"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583650435866112","@type":"Researcher","foaf:name":[{"@value":"Young‐Suk Lim"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469442883971","@type":"Researcher","foaf:name":[{"@value":"Suk Won Jung"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469442883841","@type":"Researcher","foaf:name":[{"@value":"Kang Mo Kim"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469442883840","@type":"Researcher","foaf:name":[{"@value":"Han Chu Lee"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583650435866113","@type":"Researcher","foaf:name":[{"@value":"Young‐Hwa Chung"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469442883842","@type":"Researcher","foaf:name":[{"@value":"Yung Sang Lee"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469442883969","@type":"Researcher","foaf:name":[{"@value":"Wangdon Yoo"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583650435866115","@type":"Researcher","foaf:name":[{"@value":"Soo‐Ok Kim"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2006-06","prism:volume":"43","prism:number":"6","prism:startingPage":"1385","prism:endingPage":"1391"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.21189"},{"@id":"https://journals.lww.com/01515467-200606000-00026"}],"createdAt":"2006-05-25","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017279865430272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025430173265280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025431128279936","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140544000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical course and predictive factors of virological response in long‐term lamivudine plus adefovir dipivoxil combination therapy for lamivudine‐resistant chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214486272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182238880768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182504089088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185916732416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189633761024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256640384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256676992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664610468096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Association between Serum Cytokine and Chemokine Levels and Antiviral Response by Entecavir Treatment in Chronic Hepatitis B Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593811432832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Are Humanized Mouse Models Useful for Basic Research of Hepatocarcinogenesis through Chronic Hepatitis B Virus Infection?"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204790550784","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of treatment for chronic hepatitis B using nucleos(t)ide analogues"},{"@language":"ja","@value":"核酸誘導体によるB型慢性肝炎治療の現状と課題"},{"@value":"Editorial 核酸誘導体によるB型慢性肝炎治療の現状と課題"},{"@language":"ja-Kana","@value":"Editorial カクサン ユウドウタイ ニ ヨル Bガタ マンセイ カンエン チリョウ ノ ゲンジョウ ト カダイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772373888","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of breakthrough hepatitis caused by HBV-DNA mutations after 4 years combination therapy of Lamivudine and Adefovir dipivoxil"},{"@language":"ja","@value":"ラミブジン耐性Ｂ型肝硬変に対しアデフォビル併用療法を開始し，４年後にアデフォビル耐性遺伝子変異によるｂｒｅａｋｔｈｒｏｕｇｈ　ｈｅｐａｔｉｔｉｓを認めた１例"},{"@value":"症例報告 ラミブジン耐性B型肝硬変に対しアデフォビル併用療法を開始し,4年後にアデフォビル耐性遺伝子変異によるbreakthrough hepatitisを認めた1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク ラミブジン タイセイ Bガタ カンコウヘン ニ タイシ アデフォビル ヘイヨウ リョウホウ オ カイシ シ 4ネンゴ ニ アデフォビル タイセイ イデンシ ヘンイ ニ ヨル breakthrough hepatitis オ ミトメタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679847528832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Rescue Therapy for Lamivudine-resistant Chronic Hepatitis B: Adefovir Monotherapy, Adefovir Plus Lamivudine or Entecavir Combination Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681217530368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291226257862912","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Lamivudine+Adefovir 併用療法中に耐性ウイルスの出現を疑ったB型慢性肝疾患の3症例"},{"@language":"en","@value":"Study of the development of drug resistance in three cases of hepatitis B virus with high ALT during Lamivudine+Adefovir combination therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075378198400","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Drug resistance in antiviral treatment for infections with hepatitis B and C viruses"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.21189"},{"@type":"CIA","@value":"30015138448"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.51.7329_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.3851/imp3240_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1093/infdis/jiac044_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1007/s00535-025-02211-5_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.3390/v16111743_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.2957/kanzo.47.499_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1002/jmv.22025_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1189-x_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1128/aac.00183-17_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.7883/yoken.jjid.2015.359_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1016/j.jinf.2015.09.038_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0737-2_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1007/s00535-013-0864-4_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.2957/kanzo.50.514_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.1016/j.virol.2018.08.020_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.3390/v13101920_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"},{"@type":"CROSSREF","@value":"10.3851/imp3196_references_DOI_QY8VuhaOaN5fEtVHOYw1nkqxoAq"}]}